Literature DB >> 23799497

Source terms and attenuation lengths for estimating shielding requirements or dose analyses of proton therapy accelerators.

Rong-Jiun Sheu1, Bo-Lun Lai, Uei-Tyng Lin, Shiang-Huei Jiang.   

Abstract

Proton therapy accelerators in the energy range of 100-300 MeV could potentially produce intense secondary radiation, which must be carefully evaluated and shielded for the purpose of radiation safety in a densely populated hospital. Monte Carlo simulations are generally the most accurate method for accelerator shielding design. However, simplified approaches such as the commonly used point-source line-of-sight model are usually preferable on many practical occasions, especially for scoping shielding design or quick sensitivity studies. This work provides a set of reliable shielding data with reasonable coverage of common target and shielding materials for 100-300 MeV proton accelerators. The shielding data, including source terms and attenuation lengths, were derived from a consistent curve fitting process of a number of depth-dose distributions within the shield, which were systematically calculated by using MCNPX for various beam-target shield configurations. The general characteristics and qualities of this data set are presented. Possible applications in cases of single- and double-layer shielding are considered and demonstrated.

Mesh:

Substances:

Year:  2013        PMID: 23799497     DOI: 10.1097/HP.0b013e31828c36f9

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  2 in total

1.  Shielding verification and neutron dose evaluation of the Mevion S250 proton therapy unit.

Authors:  Michael T Prusator; Salahuddin Ahmad; Yong Chen
Journal:  J Appl Clin Med Phys       Date:  2018-02-22       Impact factor: 2.102

2.  Monte Carlo Simulations of Neutron Ambient Dose Equivalent in a Novel Proton Therapy Facility Design.

Authors:  Uwe Titt; Enzo Pera; Michael T Gillin
Journal:  Int J Part Ther       Date:  2020-03-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.